McGlone Suttner Wealth Management’s Pfizer PFE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$453K Buy
18,823
+1,630
+9% +$42.6K 0.05% 137
2026
Q1
$483K Buy
17,193
+1,730
+11% +$46.1K 0.06% 128
2025
Q4
$385K Sell
15,463
-6,703
-30% -$169K 0.05% 140
2025
Q3
$565K Buy
22,166
+865
+4% +$21.4K 0.08% 108
2025
Q2
$516K Buy
21,301
+1,278
+6% +$29.8K 0.08% 113
2025
Q1
$507K Buy
20,023
+7,784
+64% +$204K 0.08% 113
2024
Q4
$325K Sell
12,239
-3,139
-20% -$85.1K 0.05% 133
2024
Q3
$445K Buy
15,378
+2,311
+18% +$67.4K 0.09% 108
2024
Q2
$376K Sell
13,067
-1,234
-9% -$34K 0.08% 106
2024
Q1
$397K Buy
14,301
+1,234
+9% +$34.2K 0.07% 111
2023
Q4
$376K Sell
13,067
-321
-2% -$9.7K 0.07% 106
2023
Q3
$444K Buy
13,388
+596
+5% +$21.1K 0.1% 80
2023
Q2
$469K Buy
12,792
+591
+5% +$23K 0.11% 79
2023
Q1
$498K Buy
12,201
+50
+0.4% +$2.16K 0.13% 72
2022
Q4
$623K Buy
+12,151
New +$583K 0.2% 59

Other funds holding PFE

McGlone Suttner Wealth Management's PFE Position: Q2 2026 in Review

McGlone Suttner Wealth Management increased its Pfizer (PFE) stake by 9.5% in Q2 2026, buying an estimated $42.6K and bringing the position to 18,823 shares worth $453K. The position accounts for 0.05% of the portfolio, ranked #137.

McGlone Suttner Wealth Management first reported a position in PFE in Q4 2022 and has held it in 15 quarters since. The position peaked at $623K in Q4 2022. 1,157 funds tracked by Wall St. Rank hold PFE as of Q2 2026.

  • McGlone Suttner Wealth Management held 18,823 shares of Pfizer worth $453K as of Q2 2026.
  • McGlone Suttner Wealth Management bought 1,630 Pfizer shares in Q2 2026, an estimated $42.6K.
  • Pfizer made up 0.05% of McGlone Suttner Wealth Management's portfolio in Q2 2026, its #137 holding.
  • McGlone Suttner Wealth Management first reported a position in Pfizer in Q4 2022 and has held it in 15 quarters since.
  • McGlone Suttner Wealth Management's Pfizer position peaked at $623K in Q4 2022.
  • 1,157 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.

Based on McGlone Suttner Wealth Management's 13F filing for Q2 2026, filed 21 Jul 2026.